NEWS & EVENTS

St. Louis biotech startup raises $25M as it prepares for commercialization

Adarza BioSystems said the funding will help it prepare for commercialization of its ZIVA platform, a biological testing device designed to assist researchers with disease profiling and drug development.

2020-02-06T14:03:46-06:00February 6th, 2020|

Adarza raises $25 million, moves toward commercialization

Adarza, based in Maryland Heights, makes diagnostic systems for researchers and drug companies. It plans to launch its testing platform commercially in June.

2020-02-06T13:57:15-06:00February 5th, 2020|

Adarza BioSystems Raises $25 Million in Series D Funding to Launch Platform for Research and Drug Development

Biotech company Adarza BioSystems announced today that it has raised $25 million in a Series D round co-led by 3x5 Partners, based in Portland, Ore., and St. Louis-based Lightchain Capital, LLC, the family office of Scottrade founder Rodger Riney. Adarza plans to use the funds to support full commercialization of ZIVA, its automated biological testing platform for academic and clinical research. Scheduled for commercial launch in June, the ZIVA platform will allow researchers to quickly identify inflammation, cardiovascular, and oncology protein biomarkers for disease profiling and drug development.

2020-02-06T13:37:24-06:00February 4th, 2020|

Adarza BioSystems to reveal ZIVA platform at AAI 2019

Adarza Biosystems, Inc. announced today that it will reveal its new protein multiplex instrument ZIVA at Immunology 2019, the annual meeting of the American Association of Immunologists (AAI) from May 9 - 13. Using a simple, time-saving workflow, the new automated system can simultaneously measure, analyze and report on up to 200 biomarkers.

2019-05-02T18:39:13-05:00May 1st, 2019|

St. Louis Business Journal: St. Louis biotech startup to launch products in 2019

Once Adarza's products launch in the second quarter of 2019, it will be one of a handful of local life sciences startups to have done so.

2018-05-23T15:23:03-05:00May 23rd, 2018|

Adarza Sets Stage for Commercialization

Adarza Biosystems, Inc., a biotechnology company developing a novel protein and biomolecule detection platform, announced today that it has put in place the leadership, new manufacturing center and branding to begin selling its technology to researchers in the second quarter of 2019.

2018-05-23T15:01:45-05:00May 23rd, 2018|

St. Louis Business Journal: RiverVest leads $17M investment in Adarza, brings on new president

RiverVest leads $17 million investment in Adarza, brings on new president

2017-09-11T12:53:54-05:00January 24th, 2017|

ADARZA BIOSYSTEMS CLOSES ON $17 MILLION SERIES C FINANCING

ROCHESTER, NY and ST LOUIS, MO (Jan. 19, 2017) – Adarza BioSystems, Inc., a leading next generation innovator in label-free, multiplex assays, announced today that it has closed a $17M Series C financing. Proceeds from the financing will be used to further expand production capacity in its St. Peters, MO manufacturing facility and fund final development and commercialization of Adarza’s first immunoassay product consumable and instrument platform. Adarza develops and manufactures immunoassay technology that can identify proteins and genetic markers in medical samples such as blood. The technology, which comes in the form of microchips, [...]

2018-05-02T01:29:44-05:00January 19th, 2017|